Stocktoria
Hyperfine, Inc. HYPR
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2021-01-27
Hyperfine, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 49.8% | 45.7% | 43.1% | 13.3% | -78.0% |
| Operating margin | -273.4% | -335.3% | -436.1% | -1084.2% | -4336.1% |
| Net margin | -262.3% | -315.9% | -401.0% | -649.2% | -4335.0% |
| FCF margin | -214.8% | -303.7% | -386.3% | -1070.2% | -3335.1% |
| Return on assets | -64.4% | -69.1% | -47.0% | -33.0% | -32.0% |
| Return on equity | -86.8% | -83.0% | -52.4% | -35.8% | -34.8% |
| Debt / equity | 0.00× | — | — | — | — |
| Current ratio | 4.34 | 6.15 | 10.14 | 14.62 | 12.55 |
| Revenue growth | 5.2% | 16.8% | 61.9% | 355.5% | 408.8% |
Source: SEC EDGAR filings · CIK 0001833769 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.